CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleLevered free cash flow is $25.52M, above the global median of $18.92M
- FinancialsAltman Z-Score 1.78: grey zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.04%
Annual Rate
CNY 0.01Paid annual
Payout Ratio
20.0%Sustainable
Last Ex-Dividend
Jul 14, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.48BCNY369.69M · vs all stocks (USD)
Trailing P/E
261.20xvs Biotechnology peers
Revenue (TTM)
1.12BCNY167.40M · vs all stocks (USD)
Profit Margin
0.87%vs Biotechnology peers
Beta
0.1420xvs all stocks
52-Week Change
-14.86%vs all stocks
Market Capitalization
2.48BCNY369.69M · vs all stocks (USD)
Enterprise Value
2.98BCNY444.09M · vs all stocks (USD)
Trailing P/E
261.20xvs Biotechnology peers
Forward P/E
4.95xvs Biotechnology peers
Price to Sales (TTM)
2.21xvs Biotechnology peers
Price to Book (MRQ)
1.41xvs Biotechnology peers
Enterprise to Revenue
2.65xvs Biotechnology peers
Enterprise to EBITDA
13.57xvs Biotechnology peers
Gross Margin
29.29%vs Biotechnology peers
Profit Margin
0.87%vs Biotechnology peers
Operating Margin
12.32%vs Biotechnology peers
Return on Assets (TTM)
1.13%vs Biotechnology peers
Return on Equity (TTM)
0.34%vs Biotechnology peers
Revenue (TTM)
1.12BCNY167.40M · vs all stocks (USD)
Revenue per Share (TTM)
5.97CNYUpdated Sep 20, 2026Quarterly Revenue Growth
14.80%vs Biotechnology peers
Gross Profit (TTM)
229.25MCNY34.21M · vs all stocks (USD)
EBITDA (TTM)
173.60MCNY25.90M · vs all stocks (USD)
Net Income (TTM)
9.77MCNY1.46M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
9.56%vs Biotechnology peers
Operating Cash Flow (TTM)
216.58MCNY32.32M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
171.01MCNY25.52M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0051CNYUpdated Sep 20, 2026Trailing Annual Dividend Yield
0.04%vs all stocks
Payout Ratio
20.00%vs Biotechnology peers
Minority Interest (Equity)
34.51MCNYFY2025 · Dec 31, 2025Revenue
1.02BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
864.32MCNYFY2025 · Dec 31, 2025Gross Profit
152.55MCNYFY2025 · Dec 31, 2025Operating Income
3.50MCNY522.39K · vs all stocks (USD)
Pre-tax Income
-77.06MCNYFY2025 · Dec 31, 2025Income Tax Expense
7.62MCNYFY2025 · Dec 31, 2025Net Income
-84.68MCNYFY2025 · Dec 31, 2025EBIT
-48.04MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
173.60MCNYFY2025 · Dec 31, 2025Research & Development
41.54MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
30.50MCNYFY2025 · Dec 31, 2025Other Operating Expenses
13.71MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.10MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
29.03MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.3900CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.3900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
187.56MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
187.56MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-84.68MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
11.53MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-52.13MCNYFY2025 · Dec 31, 2025Free Cash Flow
-131.74MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
263.27MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-84.68MCNYFY2025 · Dec 31, 2025Other Non-cash Items
31.18MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-133.82MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
135.20MCNYFY2025 · Dec 31, 2025Capital Expenditures
-79.61MCNYFY2025 · Dec 31, 2025Purchase of Investments
-3.00MCNYFY2025 · Dec 31, 2025Sale of Investments
4.13MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-78.48MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
763.05MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-718.18MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-27.76MCNYFY2025 · Dec 31, 2025Other Financing Charges
11.95MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
29.06MCNYFY2025 · Dec 31, 2025Shares Outstanding
189.70MSharesUpdated Sep 20, 2026Float Shares
99.67MSharesUpdated Sep 20, 2026% Held by Insiders
48.80%vs all stocks
% Held by Institutions
3.42%vs all stocks
Total Cash (MRQ)
260.63MCNY38.89M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.37CNYUpdated Sep 20, 2026Total Debt (MRQ)
724.75MCNY108.15M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.4036xvs Biotechnology peers
Current Ratio (MRQ)
1.26xvs Biotechnology peers
Book Value per Share (MRQ)
9.29CNYUpdated Sep 20, 2026Total Assets
2.96BCNY441.04M · vs all stocks (USD)
Total Current Assets
1.28BCNYFY2025 · Dec 31, 2025Total Liabilities
1.16BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.67BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
153.07MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.01BCNYFY2025 · Dec 31, 2025Cash
263.27MCNYFY2025 · Dec 31, 2025Cash Equivalents
31.80MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
295.07MCNYFY2025 · Dec 31, 2025Accounts Receivable
261.62MCNYFY2025 · Dec 31, 2025Inventory
477.24MCNYFY2025 · Dec 31, 2025Accounts Payable
292.26MCNYFY2025 · Dec 31, 2025Short-term Debt
668.28MCNYFY2025 · Dec 31, 2025Other Current Liabilities
469.89KCNYFY2025 · Dec 31, 2025Long-term Debt
134.88MCNYFY2025 · Dec 31, 2025Common Stock (Book)
189.70MCNYFY2025 · Dec 31, 2025Retained Earnings
198.50MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.80BCNY268.10M · vs all stocks (USD)
52-Week Low
10.63CNYUpdated Sep 20, 202652-Week High
16.27CNYUpdated Sep 20, 202652-Week Change
-14.86%vs all stocks
Beta
0.1420xvs all stocks
50-Day MA
12.65CNYUpdated Sep 20, 2026200-Day MA
13.61CNYUpdated Sep 20, 2026Avg 10-Day Volume
3.93MSharesUpdated Sep 20, 2026Avg 30-Day Volume
4.65MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.0500CNYUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 1.78: grey zoneSignificant
Altman Z-Score: 1.78
Low earnings qualitySignificant
Earnings Quality Score: -0.50
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Levered free cash flow is $25.52M, above the global median of $18.92MNotable
Levered free cash flow (USD): 25,518,713.855Global Median: 18,920,810.7
Companies that share the same coordination system — how they create, deliver, or capture value.
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Fennec Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
C4 Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
NIOX Group plc
Tier 1ProductionApproval-Gated PipelineRule
Shin Poong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Huasun Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Solara Active Pharma Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Rezolute, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Qinghai Spring Medicinal Resources Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow